“…[12,16] For many cases of AK, several treatment approaches are potentially suitable based on existing guidelines. This document therefore further complements existing guidelines and previous consensus papers by providing recommendations about selecting the appropriate Ingenol mebutate was one of the treatment options proposed for many of the profiles and this was driven by its association with good cosmetic outcomes [17,18] ; the predictable nature of the treatment and related short-term local skin reactions [19][20][21][22] ; and the fact that the administration regimen of ingenol mebutate allows for flexible use, as patients are able to decide how and when it is used according to their needs and individual condition. In a randomized, evaluator-blinded trial of ingenol mebutate 0.015% gel and diclofenac sodium 3% gel, patients experienced a shorter duration of skin reactions, with a peak after one week, with ingenol mebutate compared with diclofenac sodium, who experienced reactions throughout the 90-day treatment.…”